Vaxcyte Inc. (NASDAQ: PCVX) announced completion of enrollment in two Phase 3 clinical trials evaluating its VAX-31 pneumococcal conjugate vaccine ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE